RecruitingRecruiting
Performance of the Aktiia Optical Blood Pressure Monitoring Device Against Double Auscultation
NCT05236348 · Aktiia SA
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Single-center Prospective Clinical Trial to Validate the Performance of the Aktiia Optical Blood Pressure Monitoring (OBPM) Device at the Wrist Against Double Auscultation
About this study
According to the World Health Organization, by 2025 hypertension will affect 1.5 billion adults worldwide. Half of the adult population suffering from hypertension is currently not diagnosed and half of the treated population is not at the defined target of BP.
Widespread use of out-of-office Blood Pressure measurement is one of the proposed strategies to fight against hypertension worldwide.
Aktiia S.A. has developed an intermittent automated non-invasive cuffless blood pressure monitor, determining the values of the systolic blood pressure, the diastolic blood pressure and the heart rate. This miniature device is comfortably positioned with a bracelet on a user's wrist.
The goal of this study is to establish a reasonable assurance of safety and effectiveness with Aktiia OBPM system for monitoring blood pressure in home use.
In particular, the study will collect data from subjects by means of the device under test and collect data from subjects by means of double-auscultation, pulse oximetry and volume-clamp BP reading while subjects wear the devices at different body positions and induce Blood Pressure changes, during eight visits that will be held over the span of seven days, and generate performance reports.
Eligibility criteria
Inclusion Criteria:
* Adult subjects (aged between 21 and 85 years old)
* Subjects can read and speak French
* Subjects can perform simple physical exercises
* Subjects agreeing to attend the totality of 9 visits
* Subjects that have signed the informed consent form
Exclusion Criteria:
* Clinical staff collaborating with study PI
* Subjects with tachycardia (heart rate at rest \> 120bpm)
* Subjects with atrial fibrillation
* Subjects with diabetes
* Subjects with renal dysfunctions
* Subjects with hyper-/hypothyroidism
* Subjects with pheochromocytoma
* Subjects with Raynaud's disease
* Subjects with trembling and shivering
* Subjects with interarm systolic difference \> 15 mmHg
* Subjects with interarm diastolic difference \> 10 mmHg
* Subjects with arm paralysis
* Women in known pregnancy (for ARM 1 only)
* Subjects with an arteriovenous fistula
* Subjects with arm amputations
* Subjects with the upper arm circumference \< 22cm or \> 42 cm
* Subjects with the wrist circumference \> 21 cm
* Subjects with the exfoliative skin diseases
* Subjects with lymphoedema
Study design
Enrollment target: 225 participants
Allocation: non_randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2022-01-11
Estimated completion: 2025-03-31
Last updated: 2024-08-19
Interventions
Device: Aktiia.product-us
Primary outcomes
- • Blood pressure mean value of differences (1 week)
- • Blood pressure standard deviation of differences (1 week)
Sponsor
Aktiia SA · industry
Contacts & investigators
ContactJosep Sola, PhD · contact · josep@aktiia.com · +41797689800
InvestigatorGregoire Wuerzner, MD · principal_investigator, Service of Nephrology and Hypertension CHUV
All locations (1)
University of Lausanne HospitalsRecruiting
Lausanne, Switzerland